It operates in the world of health and science. It has 2,778 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Revenue is spread across several lines; no single product carries the company.
An average decline of 10% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades 36% below its peak. The market has trimmed its expectations for the company.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
A loss of $489.5M against $1.4B in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.7 years. After that, the company needs to find new money.
On our five-subject report card, MNKPF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MNKPF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.